CS
NUVB icon

Credit Suisse’s Nuvation Bio NUVB Stock Holding History

Credit Suisse’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-159,157
Closed -$213K – 3116
2023
Q3 		$213K Sell
159,157
-5,740
-3% -$9.55K ﹤0.01% 3017
2023
Q2 		$297K Buy
164,897
+43,408
+36% +$73.8K ﹤0.01% 3006
2023
Q1 		$202K Buy
121,489
+5,294
+5% +$10.7K ﹤0.01% 3112
2022
Q4 		$223K Buy
116,195
+31,663
+37% +$64.1K ﹤0.01% 3149
2022
Q3 		$189K Buy
84,532
+648
+0.8% +$1.85K ﹤0.01% 3271
2022
Q2 		$271K Buy
83,884
+7,115
+9% +$31K ﹤0.01% 3209
2022
Q1 		$403K Buy
76,769
+3,579
+5% +$20.1K ﹤0.01% 3091
2021
Q4 		$621K Sell
73,190
-13,183
-15% -$121K ﹤0.01% 3661
2021
Q3 		$858K Buy
86,373
+200
+0.2% +$1.81K ﹤0.01% 3460
2021
Q2 		$795K Buy
+86,173
New +$983K ﹤0.01% 3551

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's NUVB Position: Q4 2023 in Review

Credit Suisse sold out of Nuvation Bio (NUVB) in Q4 2023, closing a stake of 159,157 shares — an estimated $213K sold.

Credit Suisse first reported a position in NUVB in Q2 2021 and held it in 10 quarters. The position peaked at $858K in Q3 2021. 116 funds tracked by Wall St. Rank hold NUVB as of Q4 2023.

  • Credit Suisse reported no remaining Nuvation Bio position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 159,157 Nuvation Bio shares in Q4 2023, an estimated $213K.
  • Credit Suisse first reported a position in Nuvation Bio in Q2 2021 and held it in 10 quarters.
  • Credit Suisse's Nuvation Bio position peaked at $858K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held Nuvation Bio as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.